Patients with advanced squamous lung cancer can be treated with many kinds of monoclonal antibody drugs as prescribed by doctors, such as nabulizumab, pembrolizumab and atalizumab are better. 1. Nabulizumab: it can treat patients with advanced squamous lung cancer who are negative for EGFR gene mutation and negative for ALK gene, and who have received platinum-containing chemotherapy before, and it is a monoclonal antibody drug approved by our country with PD-1 as its target point. 2. Pembrolizumab: it is a PD-1 blocker, which can reduce the inhibitory effect of PD-1 on immune T-cells, and is suitable for the first-line treatment of patients with advanced squamous lung cancer. 3. Atelizumab: a monoclonal antibody against programmed death ligand 1 (PD-L1), which can trigger the anti-tumor response of T-cells, and is suitable for the first-line treatment of patients with advanced squamous lung cancer. Patients with advanced stage of squamous lung cancer need to actively receive treatment, choose appropriate monoclonal antibody drugs under doctor’s advice, and receive active immune-targeted therapy.